W.-S. Fang Curriculum Vitae

Weishuo Fang, Ph.D.

Professor of Medicinal Chemistry State Key Laboratory of Bioactive Substances and Functions of Natural Medicines Institute of Materia Medica, Chinese Academy of Medical Sciences 2A Nan Wei Road, Beijing, China Tel: +86(10)63165229 (office) Email: [email protected] Web: http://www.imm.ac.cn/groups/fangws LinkedIn: linkedin.com/in/weishuo-fang-a8654118/

EDUCATION

Ph. D. in Medicinal Chemistry (1993-1997), Peking Union Medical College (mentors: Profs. Xiao-tian Liang and Qicheng Fang)

B. S. in Pharmaceutical Sciences (1984-1989), College of Pharmaceutical Sciences, Beijing Medical University (currently Peking University Medical Center)

PROFESSIONAL EXPERIENCE

Professor (2016 – present) Institute of Materia Medica, Chinese Academy of Medical Sciences (IMM/CAMS), China

Visiting Scholar (2015 – 2016) Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA (advisor: Prof. Kuo-Hsiung Lee)

Chief Executive Officer (2012 – present) Nanjing Tasai Biotech Co. Ltd., China

Professor (2006-2015) Department of Natural Products Chemistry, IMM/CAMS, China

Associate Professor (2002 – 2006) Department of Natural Products Chemistry, IMM/CAMS, China

Visiting Scholar (2001-2002) Department of Biochemistry, University of Illinois at Urbana-Champaign, USA (advisor: Prof. Lowell P. Hager)

Associate Professor (1999 - 2001) Department of Natural Products Chemistry, IMM/CAMS, China

Postdoctoral Research Associate (1997 – 1999) Department of Chemistry, Florida State University, USA (advisor: Prof. Robert A. Holton) W.-S. Fang Curriculum Vitae

Research Assistant (1989-1993) IMM/CAMS

RESEARCH ACCOMPLISHMENTS

Metabolic Disease Therapy Research (2010 – Present) • Studied farnesoid X receptor (FXR) interacting agents for the therapy of various metabolic diseases, with an emphasis on diabetes and nonalcoholic steatohepatisis (NASH). Two chemotypes of FXR ligands found and patented, currently under preclinical investigations.

Translational and Drug Development in Cancer Therapy (2006 – Present) • Studied semi-synthetic taxanes for cancer chemotherapy effective against paclitaxel (Taxol)-resistant tumors. Several patented analogs are at preclinical stage, and antibody drug conjugate (ADC) technology has been applied to tumor-targeting delivery. • Discovered new agents modulating protein-protein interaction(s) between microtubule (MT) and microtubule associated protein (MAP) for selective, low to non- toxic cancer and neurodegenerative disease therapy.

Alzheimer’s Disease Therapy Research (2011 – 2018) • Researched beta-secretase (BACE) inhibitors for Alzheimer’s disease therapy. Series of conjugates, based on fragment-based drug discovery (FBDD) strategy and assisted by saturated transfer difference (STD)-NMR technique, was found effective in neuronal cells.

Photodynamic Therapy-based Antitumor Drug Development (2010 – 2015) • Involved in the development of porphyrin-based photodynamic therapeutic agents, including “Hua Bu Lin Na” which has been approved by China Food and Drug Administration (CFDA, currently NMPA) for Phase I clinical trial. • Explored the potential of porphyrin and porphyrin-like molecules to facilitate antitumor drug delivery to tumors.

HONORS AND AWARDS 4. Second-grade Award for Natural Science Research by Ministry of Education of China, 2014 3. Servier Young Investigator Award in Medicinal Chemistry by Chinese Pharmaceutical Association (sponsor: Servier Laboratories, France), 2004 2. Certificate for Excellent Doctoral Thesis of Universities and Research Institutions of China by Ministry of Education of China, 1999 1. First-grade Award for Science and Technology Progress by Ministry of Health of China, 1996

LECTURES AND SCIENTIFIC MEETING CONTRIBUTIONS Invited lectures, conferences speeches & chairs: 23. Co-chair, the 4nd Workshop on Chemistry and Biology of Microtubules and Microtubule-interacting Agents, Beijing, China, September 18-19, 2018 22. Invited talk, Dr. Tim Mitchison’s lab, Harvard Medical School, October 23, 2017. W.-S. Fang Curriculum Vitae

21. Conference speaker, 2nd International Conference and Exhibition on Marine Drugs and Natural Products. London, UK. June 15 – 17, 2017. 20. Invited lecture, the 2nd meeting of COST Action CM1407 “Challenging organic synthesis inspired by nature - from natural products chemistry to drug discovery”, Madrid, Spain, April 4 – 5, 2016 19. Invited lecture, Beijing Institute of Technology, Beijing, China, 19 Oct 2015 18. Invited lecture, School of Pharmacy, Tsinghua University, Beijing, China, October 29, 2014 17. Chair, the 2nd Workshop on Chemistry and Biology of Microtubules and Microtubule- interacting Agents, Beijing, China, September 10 – 11, 2013 16. Invited lecture, Department of Chemistry, Emory University, Atlanta, GA, USA, April 13, 2013 15. Invited lecture, Department of Biology, Hong Kong Baptist University, Hong Kong SAR, February 4, 2013 14. Invited lecture, College of Pharmacy, University, Henan, China, November 5, 2012 13. Invited speech, Sino-Europe International Conference on Pharmaceuticals 2012, Hubei, China, May 22 – 25, 2012 12. Invited lecture, Department of Molecular and Cell Biology, University of Guelph, Guelph, Canada, February 13, 2012 11. International Conference on Global Challenges for New Drug Discovery Against Tropical Parasitic Diseases, Xcaret, Mexico, December 11-15, 2011 10. Co-Chair, the 1st Workshop on Chemistry and Biology of Microtubules and Microtubule-interacting Agents, Beijing, China, November 8-9, 2011 9. Invited lecture, College of Pharmacy, Yantai University, Shangdong, China, October 23, 2011 8. Invited speech, The 3rd Chinese Taxols (Docetaxel) 360 Industrial Forum, Shanghai, China, August 11-12, 2011 7. Conference speaker, National Symposium for Medicinal Chemistry of China. Wuhan, China, October 10-13, 2009 6. Conference speaker, the 7th National Natural Organic Chemistry Symposium of China. , China, September 19-21, 2008 5. Invited lecture, College of Pharmacy, Wuhan University, Wuhan, China, September 22, 2008 4. Invited lecture, Tianjin University of Science and Technology, Tianjin, China, January 16, 2008 3. Co-Chair of Session 11, Annual Congress of Innovative Drug Discovery Science & Technology (IDDST), Xian, China, November 7-13, 2007 2. Conference speaker, Annual Congress of IDDST, Beijing, China, 7-13 Nov 2004 1. the 3rd International Symposium on Natural Drugs, Naples, Italy, October 2 -4, 2003

Abstracts and posters: 35. AACR annual meeting, Atlanta, GA, USA, March 29 – April 3, 2019 34. The 3rd RSC BMCS Medicinal Chemistry Symposium on Macrocycles, Stevenage, UK, October 8 – 9, 2018 33. European Federation of Medicinal Chemsitry – International Symposium on Medicinal W.-S. Fang Curriculum Vitae

Chemistry (EFMC-ISMC) 2018, Ljubljana, Slovenia, September 2-6, 2018 32. International Symposium for Chinese Medicinal Chemists (ISCMC), Zhengzhou, China, August 24 2-6, 2018 31. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, PA, USA, October 27 - 30, 2017 30. Chinese Medicinal Chemistry Symposium, Beijing, China, August 27 – 30, 2017 29. AACR annual meeting, New Orleans, LA, USA, April 15 -20, 2016 28. European Pharma Summit, May 5-8, 2015, Berlin, Germany 27. EACR-AACR-SIC Special Conference on Anticancer Drug Action and Drug Resistance, June 20 -23, 2015, Florence, Italy 26. EFMC-ISMC 2014 Lisbon, Portugal, September 7-11, 2014 25. AACR annual meeting, San Diego, CA, USA, April 5 -9, 2014 24. CCS 8th National Organic Chemistry Conference, Chongqing, China, October 17 -20, 2013 23. The 8th National Conference on Chemical Biology, Shanghai, China, September 15 - 18, 2013 22. The 245th ACS National Meeting & Expo, New Orleans, LA, USA, April 7-11, 2013 21. The 33rd National Medicinal Chemistry Symposium, Tucson, AZ, May 20 - 23, 2012 20. The 19th EuroQSAR, Vienna, Austria, August 26-30, 2012 19. AACR special conference on Chemical Systems Biology, Boston, MA, USA, June 27- 30, 2012 18. AAAS Annual Meeting, Vancouver, BC, Canada, February 16-20, 2012 17. Chinese Medicinal Chemistry Symposium, , China, November 17 -20, 2011 16. The 70th Annual Meeting of the Japanese Cancer Association (JCA), Nagoya, Japan, October 3 - 5, 2011 15. The 9th Tetrahedron Symposium, Beijing, China, June 22 – 25, 2010 14. EFMC-ISMC 2010, Brussels, Belgium, September 5-9, 2010 13. The 240th ACS National Meeting & Expo, Washington, DC, USA, August 22 - 26, 2010 12. AACR annual meeting, Philadelphia, PA, USA, April 17 -21, 2010 11. The 2nd International Symposium on Combinatorial Sciences in Biology, Chemistry, Catalysts and Materials, Beijing, China, September 19-23, 2009 10. The 9th AD/PD International Conference, Prague, Czech Republic, March 11 -15, 2009 9. The 5th Modern Drug Discovery and Development Summit (M3D), San Diego, CA, USA, October 14-16, 2009 8. The 7th National Natural Organic Chemistry Symposium, Chengdu, China, September 17 – 19, 2008 7. The 5th National Conference on Chemical Biology, Kunming, China, August 9 -13, 2007 6. The 7th Tetrahedron Symposium, Kyoto, Japan, May 24 – 27, 2006 5. EFMC-ISMC 2010, Istanbul, Turkey, August 29 - September 2, 2006 4. The 25th Chinese Chemistry Society Congress, Changchun, China, July 11 – 15, 2006 3. The 4th National Conference on Chemical Biology, Wuhan, China, October 9 - 12, 2005 2. FEBS Summer School on Science at the Interface of Chemistry, Biology and Medicine, Spetses Island, Greece, July 17 - 29, 2005 1. International Symposium for Chinese Inorganic Chemists (ISCIC)-5 & International Symposium for Chinese Organic Chemists (ISCOC)-8, HK SAR, China, December 19 - 22, 2004 W.-S. Fang Curriculum Vitae

RESEARCH GRANTS Government and Institutional Funding: 28. Key Technology for the Identification of Water Soluble and/or Trace Amount of Bioactive Natural Products in Traditional Chinese Medicine (2019-2020), the MOST Drug Innovation Major Project, Grant No. 2018ZX09711001-001-001 & 2018ZX09711001- 001-003, Role: Participant and co-Principal Investigator 27. Chemistry and Biological Research on Microtubule C-terminal Bindiers (2017-2022), State Key Lab Intramural Fund, Role: Principal investigator 26. Systematic Innovation and Applied Research of Natural Medicines (2016-2020), CAMS Innovation Fund for Medical Sciences (CIFMS), Grant No. 2016-I2M-1-010, Role: Participant & co-Principal investigator 25. Discovery, Optimization and functional studies of Farnesoid X receptor modulators derived from pentacyclic triterpene natural products (2015.1-2018.12), National Natural Science Foundation of China (NSFC), Grant No. 81473118, Role: Principal investigator 24. Structural Analysis Aided Optimization of Natural Products Derived Noncompetitive β- secretase Inhibitors (2013.1-2016.12), NSFC, Grant No. 81273406, Role: Principal investigator 23. Studies on New Drugs Targeting Farnesoid X Receptor (2012.6-2015.6), Ministry of Science and Technology of China (MOST), Grant No. 2012DFH30030, Role: Principal investigator 22. Studies on Druggability of LX2-32C Effective Against Drug Resistant Tumors (2012.1- 2015.12), MOST, Grant No. 2012ZX09103101-054, Role: Principal investigator 21. Natural Products Research Platform Subsidiary to General Platform for Innovative Drug Discovery (2012-2015), MOST, Grant No. 2012ZX09301002-002, Role: Participant & co-Principal Investigator 20. Digitalized Chemical Library from Traditional Chinese Medicines (2012-2013), MOST, Grant No. 2011ZX09307-002-01, Role: Participant & co-Principal Investigator 19. Optimization and Structural Activity Relationship of Antiangiogenic Triterpene- benzoquinone Conjugates (2010.1-2012.12), Beijing Natural Science Foundation, Grant No. 7102114, Role: Principal Investigator 18. Structural Optimization and Drug Like Property Evaluations of Microtubule Stablising Small Molecules with Multiple Mechanism Counteracting Drug Resistance (2010.1- 2013.12), NSFC, Grant No. 30930108, Role: Principal Investigator 17. Natural Products Research Sub-Platform Subsidiary to General Platform for Drug Discovery (2009.1-2010.12), MOST, Grant No. 2009ZX09301-003-4-1, Role: Participant & co-Principal Investigator 16. Platform for Chinese Traditional Medicine Discovery and Evaluation (2009.1-2010.12), MOST, Grant No. 2009ZX09311-004, Role: Participant & co-Principal Investigator 15. Preclinical Development of New Antitumor Taxane LX2-32C (2009.1-2010.12) subsidiary to General Platform for Drug Discovery, MOST, Grant No. 2009YZH-LCH03, Role: Principal investigator 14. Interference of Microtubule Dynamic Process with Small Molecules and Its Application to Drug Discovery (2007.1-2009.12), MOST, Grant No. 2006DFA31490, Role: Principal Investigator 13. Applied and Basic Research for the Tumor MDR Mechanism and MDR Reversal Agents W.-S. Fang Curriculum Vitae

(2007.1-2010.12). NSFC, Grant No. 30630069, Role: Participant & co-Principal Investigator 12. Preparation, Structure Activity Relationship and Mechanisitic Studies of Semi-synthetic Taxanes Effective Against Drug Resistant Tumors with Tubulin Mutations (2006.1- 2008.12), NSFC, Grant No. 20572135, Role: Principal Investigator 11. Microbial Transformation and Structural Activity Relationship of Antitumor Triterpenes (2006-2007). Key Lab of Ministry of Health of China, Role: Principal Investigator 10. Efficient and Rapid Discovery of Natural Products with Novel Structures and Their Biological Activities (2005.1-2008.12). NSFC, Grant No. 20432030, Role: Participant & co-Principal Investigator 9. Isolation and Pharmacological Evaluations of Active Compounds Exhibiting Anti- myocardial-ischemia Effect from Rhodobryum roseum, a medicinal Bryophyta (2005- 2006), Key Lab of MOE, Role: Principal Investigator 8. Biofunctional Anticancer 3-Oxo-Oleanolic Acid and Jarcaranone Conjugates (2004.1- 2005.12) IMM/CMAS, Role: Principal Investigator 7. Pursuing New Generation of Antitumor Taxol Analogues (2004.1-2006.12), Fok Ying Tong Education Foundation, Grant No. 91037, Role: Principal Investigator 6. Applied Research for the Combinatorial Biosynthesis: Production of Non-natural Terpenoids (2002.1-2004.12), NSFC, Grant No. 20172071, Role: Participant & co- Principal Investigator 5. High-throughput Screening and Integrative Studies of Chinese Traditional Medicines (2001.1-2003.12), NSFC, Grant No. 30011940, Role: Participant & co-PI 4. Antitumor Activities of Naturally Occurring Triterpenoids (2001-2002), Ministry of Personnel of China, Role: Principal Investigator 3. Studies on the Apoptosis inducing triterpene natural products (2000-2001), MOE, Role: Principal Investigator 2. Research and Development of Tranditional Medicine in the Minority Residence Regions of Western China (2000.9-2002.12), Beijing Science and Technology Committee, Grant No. 200000129, Role: Joint Principal Investigator 1. Application of tranditional and novel chemical tools to the optimization of antitumor agent Taxol and related bioactive natural products (2000.1-2004.12), Ministry of Education (MOE) of China, Grant No. 199949, Role: Principal Investigator

Industry Funded Projects: 7. Lab Scale Preparation of Taxol-porphyrin Conjugates (2016-2017). Beijing Norzer Co. Ltd., Role: Principal Investigator 6. Lab Scale Preparation of Porphyrin-Based Photodynamic Therapeutic Agents (2015- 2016). Beijing William Co. Ltd., Role: Principal Investigator 5. Lab Scale Process for the Synthesis of Carbazitaxel (2014-2015). Beijing Norzer Co. Ltd., Role: Principal Investigator 4. Development of New Antitumor Drug Aziditaxel (SFDA Categorized Chemical Agent 1.1) (2012-2016), Nanjing Taxels Co. Ltd., Role: Principal Investigator 3. Process for the Semisynthesis of Taxol (2006-2007). Guilin Huiang Co. Ltd., Role: Principal Investigator 2. Ursolic Acid Derivatives and Prodrugs for the Development of Antihepatitis B Agents (2006-2008). Jiangxi Qinglong Co. Ltd., Role: Principal Investigator W.-S. Fang Curriculum Vitae

1. Structural Activity Relationship Studies of -lactams (2004-2005). National Engineering and Technology Center-Beijing Collab Co. Ltd., Role: Principal Investigator

FULL LIST OF PUBLICATIONS (*corresponding authors, #equal contribution)

103. Yu Zhao, Tian-En Wang, Alberto Mills, Federico Gago, Wei-Shuo Fang.* Synthesis and Cytotoxicity of 7,9-O-Linked Macrocyclic C-Seco Taxoids. Molecules 2019, 24: 2161-2174. 102. Yun-Tao Ma, Yanting Yang, Pei Cai, De-Yang Sun, Pedro A. Sánchez-Murcia, Xiao- Ying Zhang, Wen-Qiang Jia, Lei Lei, Mengqi Guo, Federico Gago, Hongbo Wang,* Wei-Shuo Fang.* A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility. Journal of Natural Products 2018, 81(3): 524-533. 101. Yong Tang, Javier Rodríguez-Salarichs, Yu Zhao, Pei Cai, Juan Estévez-Gallego, Francisco Balaguer-Pérez, Isabel Barasoain, J. Fernando Díaz,* Wei-Shuo Fang*. Modification of C-seco Taxoids Through Ring Tethering and Substituent Replacement to Seek for Effective Agents Against Tumor Drug Resistance Mediated by -III Tubulin and Pgp Overexpression. European Journal of Medicinal Chemistry 2017, 137: 488- 503. 100. Guo-Ning Zhang#, Yi Huan#, Xing Wang, Su-Juan Sun, Zhu-Fang Shen, Wei-Shuo Fang*. Design, synthesis and metabolic regulation effect of farnesoid X receptor (FXR) antagonistic benzoxepin-5-ones. Chinese Chemical Letters 2017, 28(7): 1519-1522. 99. Li-qing Chen, Zhe-ming Zhang, Wei Huang*, Zhong-gao Gao*, Wei-shuo Fang, Ming- ji Jin, Lian Yu. Inhibiting the proliferation, migration and invasion of triple negative breast cancer cells through anti-tumor human serum albumin nanoparticles loading aziditaxel as a novel taxane derivative. Die Pharmazie 2017, 72(3): 152-160. 98. Dahui Zhang, Wei-Shuo Fang, Shao-Rong Wang*. An efficient semi-synthesis of 1- hydroxyl oleanolic acid analogs. Journal of Asian Natural Products Research 2017, 19(6): 595-601. 97. Shao-Rong Wang#, Tingting Xu#, Kai Deng, Chi-Wai Wong, Jinsong Liu, Wei-Shuo Fang*. Discovery of farnesoid X receptor antagonists based on a library of 3-O-esters of oleanolic acid through diverse substitution design and molecular docking methods. Molecules 2017, 22(5): 690-702. 96. Guoning Zhang, Shuainan Liu, Wenjuan Tan, Ruchi Verma, Yuan Chen, Deyang Sun, Chunming Jia, Na Wang, Yang Xu, Chiwai Wong, Zhufang Shen, Ruitang Deng, Jinsong Liu, Yanqiao Zhang, Weishuo Fang.* Synthesis and biological evaluation of chalcones and related compounds as farnesoid X receptor (FXR) antagonists. European Journal of Medicinal Chemistry 2017, 129: 303-309. 95. Guangyao Lv, Dengjun Sun, Jingwen Zhang, Xiaoxia Xie, Xiaoqiong Wu, Weishuo Fang, Jingwei Tian, Chunhong , Hongbo Wang,* Fenghua Fua.* Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo. Acta Pharmaceutica Sinica B 2017, 7(1): 52-58. 94. Li-qing Chen, Wei Huang, Zhong-gao Gao, Wei-shuo Fang, Ming-ji Jin. Lx2-32c– loaded polymeric micelles with small size for intravenous drug delivery and their W.-S. Fang Curriculum Vitae

inhibitory effect on tumor growth and metastasis in clinically associated 4T1 murine breast cancer. International Journal of Nanomedicine 2016, 11: 5457–5472. 93. Hua Sun, Partick Y. K. Yue, Shao-Rong Wang, Lihong Huo, Ying Zhao, Songbo Xie, Jens Vindahl Kringelum, Ole Lund, Olivier Taboureau, Jun Zhou, Ricky N. S. Wong and Wei-Shuo Fang.* Synthesis and biological evaluations of cytotoxic and antiangiogenic triterpenoids-Jacaranone conjugates. Medicinal Chemistry 2016, 12(8): 775-785. 92. CHEN Li-qing, HUANG Wei,* GAO Zhong-gao,* FANG Wei-shuo, JIN Ming-ji. Preparation, Pharmaceutical Characterization and in Vitro Anti-tumor Effects of Aziditaxel-loaded mPEG-PLA Micelles. Chinese Pharmaceutical Journal 2015, 50(19): 1688-1695. 91. Shao-Rong Wang, Pedro Sánchez-Murcia, Federico Gago, Wei-Shuo Fang*. A Novel C,D-Spirodioxene Taxoid Synthesized through an Unexpected Pd-Mediated Ring Cyclization. Organic & Biomolecular Chemistry 2016, 14(1): 345-352. 90. Shao-Rong Wang, Chun-Gang Yang, Pedro Sánchez-Murcia, James Snyder, Ning Yan, Gonzalo Sáez Calvo, J. F. Diaz, Federico Gago, Wei-Shuo Fang*. Restoration of Microtubule Interaction and Cytotoxicity in D-seco Taxanes Upon Incorporation of 20- Hydroxymethyl-4-Allyloxy Groups. Organic Letters 2015, 17(24): 6098-6101. 89. Benet Pera, M. Nieves Calvo-Vida, Srikanth Ambati, Michel Jordi, Alissa Kahn, J. Fernando Díaz, Weishuo Fang, Karl-Heinz Altmann, Leandro Cerchietti,* Malcolm A.S. Moore. High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells. Cancer Letters 2015, 368(1): 97-104. 88. Hongbo Wang*, Jianqiao Zhang, Guangyao Lv, Jinbo Ma, Pengkai Ma, Guangying Du, Zongliang Wang, Jingwei Tian, Weishuo Fang, Fenghua Fu*. Preparation, Pharmacokinetics, Biodistribution, Antitumor Efficacy and Safety of Lx2-32c- Containing Liposome. PLoS ONE 2014, 9(12): e114688. 87. Ruth Matesanz, Chiara Trigili, Javier Rodríguez-Salarichs, Ilaria Zanardi, Benet Pera, Aurora Nogales, Wei-Shuo Fang, Jesús Jímenez-Barbero, Ángeles Canales, Isabel Barasoain, Iwao Ojima, J. Fernando Díaz. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances. Bioorganic & Medicinal Chemistry, 2014, 22(18): 5078-5090. 86. Pei Cai, Peihua Lu, Frances J Sharom, Wei-shuo Fang.* A semisynthetic taxane Yg-3- 46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro. Cancer Letters 2013, 341(2): 214-223. 85. Jian-qin Zhu, Hui Chen, Kai Deng, Shao-rong Wang, Yan Li, Wei-shuo Fang.* Synthesis and hepatoprotective activity of glycoside conjugates of ursolic acid. Chemical Journal of Chinese Universities 2013, 34(7): 1660-1666. 84. Claire Coderch#, Yong Tang#, Javier Klett, Shu-En Zhang, Yun-Tao Ma, Shaorong Wang, Antonio Morreale, Ruth Matesanz, Benet Pera, Angeles Canales, Jesús Jiménez-Barbero, José-Fernando Díaz, Wei-Shuo Fang,* and Federico Gago.* A structure-based design of new C2- and C13-substituted taxanes: tubulin binding affinities and extended QSAR using COMBINE analysis. Organic & Biomolecular Chemistry 2013, 11(18): 3046-3056. 83. Giorgio Maccari, Mattia Mori, Javier Rodríguez-Salarichs, Weishuo Fang, José W.-S. Fang Curriculum Vitae

Fernando Díaz, Maurizio Botta.* Free Energy Profile and Kinetics Studies of Paclitaxel Internalization from the Outer to the Inner Wall of Microtubules. Journal of Chemical Theory and Computation 2013, 9(1): 698-706. 82. Laura Cosentino, Mariano Redondo-Horcajo, Ying Zhao, Ana Rita Santos, Kaniz F Chowdury, Victoria Vinader, Qasem M A Abdallah, Hamdy Abdel-Rahman, Jérémie Fournier-Dit-Chabert, Steven D Shnyder, Paul M. Loadman, Wei-shuo Fang, José Fernando Díaz, Isabel Barasoain, Philip A. Burns, Klaus Pors.* Synthesis and biological evaluation of colchicines B ring analogues tethered with halogenated benzyl moieties. Journal of Medicinal Chemistry 2012, 55(24), 11062-11066. 81. Qing Zhou, Yan Li, Liwei Liang, Zhixiang Zhu, Weishuo Fang, Xiaoguang Chen.* Lx2- 32c, a Novel Taxane Derivative, Exerts Anti-resistance Activity by Initiating Intrinsic Apoptosis Pathway in Vitro and Inhibits the Growth of Resistant Tumor in Vivo. Biological & Pharmaceutical Bulletin 2012, 35(12): 2170-2179. 80. Jia-Yi Tao, Jun Zhao, Ying Zhao, Yan-Mei Cui, Wei-Shuo Fang*. BACE inhibitory flavanones from Balanophora involucrata Hook. F. Fitoterapia 2012, 83(8): 1386-1390. 79. Jia-Yi Tao, Sheng-Jun Dai, Feng Zhao, Jun-Feng Liu, Wei-Shuo Fang, Ke Liu.* New ursane-type triterpene with NO production suppressing activity from Nauclea officinalis. Journal of Asian Natural Products Research 2012, 14(2): 97-104. 78. Shu-En Zhang, Jia-Yi Tao, Ying Zhao, Shao-Rong Wang, Di Zhou, Wei-Shuo Fang.* Isolation, identification, semi-synthesis of aziditaxel derivatives and their biological evaluation. Journal of Asian Natural Products Research 2012, 14(5): 463-475. 77. Jiayi Tao, Weishuo Fang.* Chemical constituents from Sambucus chinensis. Chinese Journal of Chinese Materia Medica 2012, 37(10): 1399-1401. 76. Guoning Zhang, Wei-shuo Fang.* A new and efficient synthesis of cabazitaxel. Journal of Chinese Pharmaceutical Sciences 2012, 21(5): 472-476. 75. Shaorong Wang, Weishuo Fang.* Design and Synthesis of a Dual Linker for Solid Phase Synthesis of Oleanolic Acid Derivatives. Molecules 2011, 16(6): 4748-4763. 74. Jian-qing Zhu, Hui Chen, Jia-yi Tao, Yan Li, Wei-shuo Fang.* Synthesis and hepatoprotective activity of three amino acid conjugates of ursolic acid. Chinese Journal of Medicinal Chemistry 2011, 21(3): 232-235. 73. Xi Xiao, Ju Wu, Chiara Trigili, Hui Chen, Joseph W.K. Chu, Ying Zhao,Peihua Lu, Li Sheng, Yan Li, Frances J. Sharom, Isabel Barasoain, J. Fernando Diaz, Wei-shuo Fang.* Effects of C7 substitutions in a high affinity microtubule-binding taxane on antitumor activity and drug transport. Bioorganic & Medicinal Chemistry Letters 2011, 21(16): 4852-4856. 72. Peng Wang, Ying Zhao, Ping Zhu, Weishuo Fang.* Expression and purification of human β-secretase (BACE1) in Pichia pastoris. Chinese Journal of Biotechnology 2011, 27(11): 1655-1666. 71. Ruth Matesanz, Javier Rodríguez-Salarichs, Benet Pera, Ángeles Canales, José Manuel Andreu, Jesús Jiménez-Barbero, Wim Bras, Aurora Nogales, Wei-Shuo Fang, José Fernando Díaz. Modulation of microtubule interprotofilament interactions by modified taxanes. Biophysical Journal 2011, 101(12): 2970-80. 70. Qing-Yun Yang, Chun-Suo Yao, Wei-Shuo Fang.* A new triglucosylated naphthalene glycoside from Aloe vera L. Fitoterpia 2010, 81(1): 59-62. W.-S. Fang Curriculum Vitae

69. Isabel Barasoain, Ana M. García-Carril, Ruth Matesanz, Giorgio Maccari, Chiara Trigili, Mattia Mori, Jing-Zhe Shi, Wei-Shuo Fang, José M. Andreu, Maurizio Botta, J. Fernando Díaz*. Probing the pore drug binding site of microtubules with fluorescent taxanes: Evidence of two binding poses. Chemistry & Biology 2010, 17(3):243-53. 68. Xiao-Yan Tian, Ying Zhao, Shi-Shan Yu, Wei-Shuo Fang.* BACE1 Inhibitory Phenolic Acids and A Novel Sesquiterpenoid from Homalomena occulta. Chemistry & Biodiversity 2010, 7(4): 984-992. 67. Liang Lv, Xiao-Yan Tian, Wei-Shuo Fang.* Three new antioxidant C-glucosylanthrones from Aloe nobilis. Journal of Asian Natural Products Research 2010, 12(6): 443-447. 66. Na Guo, Ying Zhao, Wei-shuo Fang.* Biotransformation of 3-oxo-oleanolic acid by Absidia glauca Hagem. Planta Medica 2010, 76(10): 1904-1907. 65. Xiao-Yan Tian, Ying-Hong Wang, Qing-Yun Yang, Shi-Shan Yu, Wei-Shuo Fang.* Jacaranone Analogues from Senecio scandens. Journal of Asian Natural Products Research 2009, 11(1): 63-68. 64. Xuan Li, Ruth Matesanz, Isabel Barasoain, José Fernando Díaz,* Wei-Shuo Fang.* Synthesis and Biological Activities of High Affinity Taxane Based Fluorescent Probes. Bioorganic & Medicinal Chemistry Letters 2009, 19(3): 751-754. 63. Li Zhang, Juan-Juan Hu, Jian-Wei Lin, Wei-Shuo Fang, Guan-Hua Du.* Anti- inflammatory and analgesic effects of ethanol and aqueous extracts of Pterocephalus hookeri (C.B. Clarke) Höeck. Journal of Ethnopharmacology 2009, 123(3): 510-514. 62. Ying Zhao, Wei-Shuo Fang,* Klaus Pors. Microtubule Stabilising Agents for Cancer Chemotherapy. Expert Opinions on Therapeutic Patents 2009, 19(5): 607-622. 61. Shao-Rong Wang, Wei-Shuo Fang.* Pentacyclic Triterpenoids and Saponins with Apoptosis-inducing Activity. Current Topics in Medicinal Chemistry 2009, 9(16): 1581- 1596. 60. Hua Sun, Chun Hu, Wei-Shuo Fang.* Synthesis, water solubility and antitumor activity of amino acid conjugates of 3-oxoleanolic acid. Chinese Journal of Medicinal Chemistry 2008, 18 (1): 11-15. 59. Jin Qu, Wei-shuo Fang, Shi-shan Yu*, De-quan Yu. New Approaches to Identification and Direct Isolation of Novel Bioactive Compounds from Natural Products. Chinese Journal of Natural Medicines 2008, 6(1): 6-12. 58. Hua Sun, Chun Hu, Wei-Shuo Fang.* An Efficient Semi-synthesis and Structure Revision of a cytotoxic triterpenoid 25-acetoxy-3α-hydroxyolean-12-en-28-oic acid from Liquidamber styraciflua. Journal of Asian Natural Products Research 2008, 10(4): 271-276. 57. Liang Lv, Qing-Yun Yang, Ying Zhao, Chun-Suo Yao, Yang Sun, Eun-Ju Yang, Kyung- Sik Song, Inhee Mook-Jung, Wei-Shuo Fang.* BACE-1 (-secretase) Inhibitory Chromone Glycosides from Aloe vera and Aloe nobilis. Planta Medica 2008, 74(5): 540-545. 56. Ruth Matesanz, Isabel Barasoain, Chung-gang Yang, Lei Wang，Xuan Li, Concepción de Inés, Claire Coderch, Federico Gago, Jesús Jiménez-Barbero, JoséManuel Andreu, Wei-Shuo Fang,* José Fernando Díaz.* Optimization of taxane binding to microtubules. Binding affinity decomposition and incremental construction of a high- affinity analogue of paclitaxel. Chemistry & Biology 2008, 15(6): 573-585. W.-S. Fang Curriculum Vitae

55. Wang Hong-bo, Li Hong-yan, Fang Wei-shuo, Chen Xiao-guang.* Inhibiting effect of Lx2-32c,one taxane derivant,on the proliferation of human ovary A2780 cells. Chinese Journal of New Drugs 2008, 17(10): 833-836. 54. Hongbo Wang, Hongyan Li, Minxin Zuo, Yi Zhang, He Liu, Weishuo Fang, Xiaoguang Chen.* Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo. Cancer Letters 2008, 268(1): 89-97. 53. Wei-Shuo Fang,* Shao-Rong Wang. Structural Studies of Taxol Analogues for Drug Discovery. Expert Opinions on Drug Discovery 2008, 3(9): 1109-1122. 52. Dong Wang, Xiao-qiu Liu, Chun-suo Yao, Wei-shuo Fang.* Studies on the Chemical Constituents from Botrychium lanuginosum Wall. Chinese Journal of Chinese Materia Medica 2008, 33(22): 2627-2629. 51. Qing-yun Yang, Xiao-yan Tian, Wei-shuo Fang.* Bioactive coumarins from Boenninghausenia sessilicarpa. Journal of Asian Natural Products Research 2007, 9(1): 59-65. 50. Chung-gang Yang, Isabel Barasoain, Xuan Li, Ruth Matesanz, Ronghua Liu, Frances J. Sharom, Da-Li Yin, J. Fernando Díaz,* Wei-Shuo Fang.* Overcoming Tumor Drug Resistance with High Affinity Taxanes: A SAR Study of C-2 Modified 7-Acyl-10- Deacetyl Cephalomannines. ChemMedChem 2007, 2(5): 691-701. 49. Lei Wang, Ana A. Alcaraz, Ruth Matesanz, Chun-Gang Yang, Isabel Barasoain, J. Fernando Díaz, Ye-Zhi Li, James P. Snyder, Wei-Shuo Fang.* Synthesis, Biological Evaluation and Tubulin Binding Poses of C-2 Sulfur Linked Taxol Analogues. Bioorganic & Medicinal Chemistry Letters 2007, 17(11): 3191-3194. 48. Lei Wang, Qing-chuan Zheng, Zhi-guang Song, Wei-shuo Fang, Ye-zhi Li, Hua-min Huang.* Association of (S)-Isoserine Derivatives and 2,2,4-Trimethyl-3-hydroxy-4- cyclohexene-carboxylate. Chemical Research in Chinese Universities 2007, 23(1): 18-21. 47. Wen-Zhao Wang, Wei-Shuo Fang.* Purification Techniques for Liquid-phase Combinatorial Synthesis. Youji Huaxue (Chinese Journal of Organic Chemistry) 2007, 27(12): 1452-1462. 46. Xiao-yan Tian, Ying-hong Wang, Hong-yue Liu, Shi-shan Yu, Wei-shuo Fang.* On the Chemical Constituents of Dipsacus asper. Chemical & Pharmaceutical Bulletin, 2007, 55(12): 1677-1681. 45. Xiaoyan Tian, Yunshan Wu, Gong, Yang Lu, Weishuo Fang.* (3aRS, 7aRS) - 3a-hydroxy-3,3a,7,7a-tetrahydrobenzofuran-2,6-dione. Acta Crystallographia Section E 2006, 62: O458-O459. 44. Dan Huang, Yan Ding, Yan Li, Weiming Zhang, Weishuo Fang, Xiaoguang Chen.* Anti- tumor activity of a 3-oxo derivative of oleanolic acid. Cancer Letters 2006, 233(2): 289- 96. 43. Xiao-yan Tian, Ying-hong Wang, Shi-shan Yu, Wei-shuo Fang.* Two Novel Tetrairidoid Glucosides from Dipsacus asper. Organic Letters 2006, 8(10): 2179-2182. 42. Xiao-yan Tian, Ying-hong Wang, Qing-yun Yang, Xin Liu, Wei-shuo Fang,* Shi-shan Yu. Jacaranone Glycosides from Senecio Scandens. Journal of Asian Natural Products Research. 2006, 8(1-2): 125-132. 41. Qin-yun Yang, Wei-shuo Fang.* Chemical constituents and pharmacological activities W.-S. Fang Curriculum Vitae

of Aloe genus. Natural Products R&D. 2006, 18(suppl): 172-178. 40. Lei Wang, Ye-Zhi Li, Huan-min Huang, Wei-Shuo Fang.* Catalytic Enantioselective Ring Opening of Epoxides. Youji Huaxue (Chinese Journal of Organic Chemistry). 2006, 26(9): 1208-1216. 39. Bo Gao, Chun-suo Yao, Jin-yun Zhou, Ruo-yun Chen, Wei-shuo Fang.* Studies on the active constituents as inhibitors of BACE from Aloe arborescen. Acta Pharmaceutica Sinica 2006, 41(10): 1000-1003. 38. Hua Sun, Wei-Shuo Fang,* Wen-Zhao Wang, Chun Hu. Structure-activity Relationships of oleanane-and Ursanetype Triterpenoids. Botanical Studies (Botanical Bulletin of Academia Sinica) 2006, 47(4): 339-368. 37. Wei-Shuo Fang,* Xiao-Tian Liang. Recent Progress in Structure Activity Relationship and Mechanistic Studies of Taxol Analogues. Mini Reviews in Medicinal Chemsitry. 2005, 5(1): 1-12. 36. Wei-Shuo Fang,* Hong-Yan Liu, Qi-Cheng Fang. Synthesis and antitumor activity of C-2/C-10 modified analogues of Docetaxel. Chinese Chemical Letters 2005, 16(1): 38-40. 35. Wen-jie Lu, Teng-fei Ji, Jia-yuan Chen, Hong Wei, Wei-shuo Fang.* Isoflavones from Abrus mollis. Zhongcaoyao (Chinese Herbal Medicines) 2004, 35(12): 1331- 1333. 34. Qiyun Yang, Weishuo Fang.* A Survey to Chemical Constituents and Pharmacological Studies on Boenninghausenia sp.. Natural Products Research and Development 2003, 15(1): 66-70. 33. Wenjie Lu, Xiaoyan Tian, Jiayuan Chen, Hong Wei, Weishuo Fang.* Studies on Chemical Constituents of Abrus mollis. Western China Pharmaceutical Journal 2003, 18(6): 406-408. 32. Xiandao Pan, Weishuo Fang. Recent Progress in Structure-Activity Relationship Studies on Anti-cancer Drug Colchicine and its derivatives. Acta Pharmaceutica Sinica 2002, 37(10): 821-831. 31. Weishuo Fang, Kedi Cheng.* Application of Peroxidases in asymmetric oxidation and its mechinistic studies. Youji Huaxue (Chinese Journal of Organic Chemistry) 2002, 22(10): 710-717. 30. Wei-Shuo Fang,* Ying Liu, Hong-Yan Liu, Shao-Feng Xu, Liang Wang, Qi-Cheng Fang. Syntheis and cytotoxicity of 2-amido docetaxel analogues. Bioorganic & Medicinal Chemistry Letters 2002, 12(11): 1543-1546. 29. Wei-Shuo Fang,* Ying Liu, Qi-Cheng Fang. First Synthesis of 2-thiol ether analogue of docetaxel. Chinese Chemical Letters 2002, 13(8): 708-710. 28. Wei-Shuo Fang,* Qi-Cheng Fang and Xiao-Tian Liang. Synthesis of 2-benzyolamido analog of docetaxel. Tetrahedron Letters 2001, 42(7): 1331-1333. 27. Hong Xu, Weishuo Fang, Xiao-Guang Chen, Wei-Yi He, Ke-Di Cheng.* Cytochalashin D from Hypocrella bambusae. Jouranl of Asian Natural Products 2001, 3(3): 151-155. 26. Weishuo Fang, Qicheng Fang* and Xiaotian Liang. Synthesis of 14-bromo and 14- hydroxy baccatin III derivatives. Chinese Chemical Letters 2001, 12(8): 675-678. 25. Guang-Ming Liu, Wei-Shuo Fang,* Jin-Fu Qian, Hai Lan. Distribution of paclitaxel and its congeners in Taxus mairei. Fitoterapia 2001, 72(7): 743-746.

Papers published as PhD student and research assistant: W.-S. Fang Curriculum Vitae

24. Weishuo Fang, Qicheng Fang,* Xiaotian Liang. Chemical Reactivity and Structure Modification of the core structure of Taxol and its analogue. Acta Pharmaceutica Sinica 1998, 33(4): 310-320. 23. Wei-shuo Fang, Qi-cheng Fang,* Xiao-tian Liang. The ephemeral 10-OH trifluoro- methanesulfonates of 7-epi paclitaxel analogs-A new example for anchimeric assistance. Chinese Chemical Letters 1998, 9(1): 29-33. 22. Nan Wu, Yang Lv,* Qitai Zheng, Weishuo Fang, Yongli Gao, Qicheng Fang, Tonghui Zhou. Studies on the fine stereostructures of taxane diterpenoids. Acta Pharmaceutica Sinica 1998, 33(10): 759-763. 21. Qicheng Fang,* Weishuo Fang. Advances in the studies on Paclitaxel. Zhongcaoyao (Chinese Medicinal Herbs). 1997, 28(supplement): 240-244. 20. Wei-shuo Fang, Qi-cheng Fang,* Xiao-tian Liang, Yang Lu, Nan Wu, Qi-tai Zheng. Taxuchin B, a new chlorine-containing taxoid. Chinese Chemical Letters 1997, 8(3): 231-232. 19. Wei-shuo Fang, Qi-cheng Fang*, Xiao-tian Liang. Reinvestigation to the C-7- epimerization of paclitaxel and related taxoids under basic conditions. Synthetic Communications 1997, 27(13): 2305-2310. 18. Wei-shuo Fang, Qi-cheng Fang*, Xiao-tian Liang. Preliminary studies on acylation of 10-OH and 7-OH in 7-epi-10-deacetylpaclitaxel. Chinese Chemical Letters 1997, 8(10): 847-848. 17. Hong Xu, Kedi Cheng,* Weishuo Fang, Ping Zhu and Chao Meng. A new taxoid from microbial transformation. Chinese Chemical Letters 1997, 8(12): 1055-1056. 16. Guang-ming Liu, Wei-Shuo Fang,* Xu-xiang Zhu. Content of paclitaxel and its related compounds in different parts of Taxus yunnanensis. Fitoterapia 1996, 67(2): 149-152. 15. Weishuo Fang, Ran Huo, Qicheng Fang.* Content of taxol precursors 10- deacetylbaccatin III and baccatin III in Taxus cuspidata. Zhongcaoyao (Chinese Traditional and Herbal Drugs) 1996, 27(6): 339-340. 14. Ke-di Cheng,* Wei-shuo Fang, Yu-jun Yang, Hong Xu, Chao Meng, Man Kong, Wen-yi He, Qi-cheng Fang. C-14 oxygenated taxanes from Taxus yunnanensis cell cultures Phytochemistry 1996, 42(1): 73-75. 13. Nan Wu, Yang Lu, Qi-tai Zheng, Wei-shuo Fang, Xiao-jie Tong, Qi-cheng Fang.* Crystal structure of taxinine A. Chinese Journal of Structure Chemistry 1996, 15(5): 387-390. 12. Wei-shuo Fang, Qi-cheng Fang,* Xiao-tian Liang. Bicyclic taxoids from needles of Taxus chinensis. Planta Medica 1996, 62(6): 567-569. 11. Wei-shuo Fang, Yue Wu, Jin-yun Zhou, Wei-ming Chen and Qi-cheng Fang.* Determination of 10-deacetylbaccatin III and baccatin III in Taxus yunnanesis. Journal of Chinese Pharmaceutical Sciences 1995, 4(1): 47-50. 10. Wei-shuo Fang, Qi-cheng Fang,* Xiao-tian Liang, Yang Lu and Qi-tai Zheng. Taxachitrienes A and B, two new bicyclic taxane diterpenoids from Taxus chinensis. Tetrahedron 1995, 51(31): 8483-8490. 9. Xiao-jie Tong, Wei-shuo Fang, Jin-yun Zhou, Cun-heng He, Wei-ming Chen and Qi- Cheng Fang.* Three new taxane diterpenoids from needles and stems of Taxus cuspidata. Journal of Natural Products 1995, 58(2): 233-238. 8. Weishuo Fang. Progress in Antitumor Natural Prodcuts. Guowai Yixue Yaoxue Fence W.-S. Fang Curriculum Vitae

1994, 21(5): 264-269. 7. Weishuo Fang. Chemical Studies of Taxol. Chinese Pharmaceutical Journal 1994, 29(5): 259-263. 6. Xiaojie Tong, Weishuo Fang, Jinyun Zhou, Cunheng He, Weiming Chen, Qicheng Fang.* Chemical studies of twigs and leaves of Taxus cuspidata. Acta Pharmaceutica Sinica 1994, 29(1): 55-60. 5. Weishuo Fang, Yue Wu, Jinyun Zhou, Weiming Chen and Qi-Cheng Fang.* Qualitative and quantitative determination of taxol and related compounds in Taxus cuspidata Sieb et Zucc. Phytochemical Analysis 1993, 4(3): 115-119. 4. Xiao-Jie Tong, Wei-shuo Fang, Jin-yun Zhou, Cun-heng He, Wei-ming Chen and Qi- cheng Fang.* Studies on the chemical constituents of Taxus cuspidata. Chinese Chemical Letters 1993, 4(10): 887-890. 3. Weishuo Fang. Recent Progress in Antitumor Natural Products. Chinese Pharmaceutical Journal 1993, 28(8): 456-460. 2. Weishuo Fang. Antitumor Actions of Flavone-8-acetic acid (FAA). Guowai Yixue Yaoxue Fence 1992, 19(3): 135-139. 1. Xia Li, Weishuo Fang, Rongzhi Li.* Spectrometric determination of columbianetin in Angelica pubescens extracts. Zhongcaoyao (Chinese Medicinal Herbs) 1990, 21(2): 59-60.

PATENTS 1. Jungui Dai, Xionghui Chao, Jianhua Li, Jian Li, Zhijian Ding, Weishuo Fang. A Microbe Capable of Hydrolizing 7-Xyloside and C13 Side Chain of Taxanes. ZL200810223201.2 2. Weishuo Fang, Xiaoyan Tian, Ying Zhao. Beta-secretase Inhibitory Components in Homalomena occulta. ZL200710175803.0 3. Weishuo Fang, Xiaoguan Chen, Chungang Yang, Xuan Li, Hongbu Wang, Hongyan Liu, Rui Han, Limin Zhao. Cephalomannine Derivatives, A Process for Their Preparation, and A Pharmaceutcial Composition Thereof and The Use Thereof. ZL200610080890.7 4. Robert A. Holton, Weishuo Fang. C10 carbamoyloxy substituted taxane compositions. US 7,230,013

BOOK AND BOOK CHAPTERS Book: 1. Xiao-tian Liang, Wei-shuo Fang (ed.) Medicinal Chemistry of Bioactive Natural Products. Wiley Interscience (Hoboken, NJ, USA), 2006, p.1-440.

Book chapters: 5. Wei-Shuo Fang, Deyang Sun, Shuang Yang, Na Guo. β-Secretase (BACE1) Inhibitors from Natural Products. In: P. B. Andrade, P. Valentão and D. M. Pereira (eds) Natural Products Targeting Clinically Relevant Enzymes, Wiley-VCH Verlag, Weinheim, Germany. 2017, p.93-134. 4. Shao-rong Wang, Wei-shuo Fang. Structure modifications of taxol and the interactions of these analogues with microtubules. In: Institute of Materia Medica, Chinese Academy of Medical Sciences (ed.) Modern Studies of Traditional Chinese Medicine, Peking Union Medical College Press (Beijing), 2010, p.859-881. W.-S. Fang Curriculum Vitae

3. Weishuo Fang, Qicheng Fang, Xiaotian Liang. Structural Modifications and Their Influences on Antitumor and Other Related Activities of Taxol and Its Analogs. In: Xiao- tian Liang, Wei-shuo Fang (ed.) Medicinal Chemistry of Bioactive Natural Products. Wiley Interscience (Hoboken, NJ, USA), 2006, p.73-141. 2. Weishuo Fang. Structural Modifications and Practical Organic Transformations in Medicinal Chemistry of Natural Products. In: Qicheng Fang (ed.) Progress in Chemistry of Natural Medicines, Peking Union Medical College Press (Beijing), 2006, p.144-182. 1. Xuemei Liu, Ying Zhao, Weishuo Fang. Amino Acids, Peptides and Proteins. In: Qicheng Fang (ed.) Progress in Chemistry of Natural Medicines, Peking Union Medical College Press (Beijing), 2006, p.705-755.

SERVICE

MEMBERSHIP, EDITORIAL AND REVIEWER ACTIVITIES Senior Member: Chinese Pharmaceutical Association (CPS) since 2000 Member: American Chemical Society (ACS) since 2001; American Association for Advancement of Science (AAAS) since 2005, American Association for Cancer Research (AACR) since 2009 Science Advisory Board: Key Laboratory of Natural Medicine and Immune-Engineering of Henan Province, China, since 2010 Editorial Advisory Board: The Open Organic Chemistry Journal (2008-2015), BAOJ Pharmaceutical Sciences (2016-) Guest Editor: Current Topics in Medicinal Chemistry (“Natural Products” themed issues, 2009) Journal Reviewer: Accounts of Chemical Research, Acta Chimica Sinica, Acta Pharmaceutica Sinica, Australian Journal of Chemistry, Bioorganic & Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, BMC Alternative Complementary and Alternative Medicine, Cancer Biology, Carbohydrate Polymers, China Pharmaceutical Journal, Chinese Chemical Letters, Chinese Journal of Organic Chemistry, Current Topics in Medicinal Chemistry, European Journal of Medicinal Chemistry, Journal of Asian Natural Products Research, Journal of Organic Chemistry, MedChemComm, Organic Letters, Phytochemical Letters, Planta Medica, Science in China, The Open Organic Chemistry Journal, etc. Book Reviewer: John Wiley & Sons, Springer, Wiley-VCH, Science Press (China) Grant Reviewer: National Natural Science Foundation of China (NSFC), Ministry of Science and Technology of China, Ministry of Education of China, Foundation for Science and Technology of Portugal (FCT) Doctoral Thesis Reviewer: Chinese Academy of Sciences, Chinese Academy of Medical Sciences, National University of Singapore

TEACHING

MENTORING ACTIVITIES Granduate students: 15 doctoral, 14 master, and 5 visiting/jointly supervised students Xiaoyan Tian (2001-06), graduated as PhD, currently staff manager at Journal of Asian Natural Products Research editorial office W.-S. Fang Curriculum Vitae

Chungang Yang (2002-07), graduated as PhD, currently Lawyer and Patent Attorney at Zhongzi Law Office Huan Chen (2002-04), visiting master student from Shenyang Pharmaceutical University Chunyan Han (2003-05), master student, currently working in Pharmaron Bo Gao (2003-06), graduated as MSc, currently editor at People’s Medical Publishing House Qingyun Yang (2003-06), graduated as MSc, currently associate professor at Chinese Academy of Medical Sciences Hua Sun (2003-07), visiting PhD student from Shenyang Pharmaceutical University, currently associate professor at Tianjin University of Science and Technology Lei Wang (2004-06), visiting PhD student from Jilin University, currently associate professor at Jilin University Wenzhao Wang (2004-07), graduated as MSc, currently pharmacist-in-charge at Beijing Xicheng District Food & Drug Safety Monitoring Center Shaorong Wang (2004-09), graduated as PhD, currently reviewer at National Medical Products Administration of China Liang Lv (2005-07), master student, currently director of R&D center of innovative agrochemicals, CAC Group Anping Chen (2005-09), graduated as PhD Xi Xiao (2005-09), graduated as MSc, currently HR manager at Tencent Holdings Na Guo (2005-11), graduated as PhD, currently research associate professor at Tianjin University of Science and Technology Dong Wang (2006-08), visiting master student from Shenyang Pharmaceutical University, currently scientist at Tianjin Cancer Hospital Ju Wu (2006-09), graduated as MSc Jianqin Zhu (2006-09), graduated as MSc, currently as registration affairs staff in Haida Pharmaceuticals Company Peng Wang (2007-10), graduated as MSc Shuen Zhang (2007-12), graduated as PhD, currently reviewer at Patent Examination Cooperation (Beijing) Center of the Patent Office, CNPA Jiayi Tao (2008-11), graduated as PhD, currently research associate at Chinese Academy of Medical Sciences Kai Deng (2009-2011), visiting master student from Heilongjiang University of Chinese Medicine, currently R&D engineer at the 4th Changzhou Pharmaceutical Company Di Zhou (2009-12), PhD student Yuntao Ma (2009-15), graduated as PhD, currently group leader at Huahai Pharmaceutical Company Yong Tang (2009-13), graduated as PhD, currently medical adviser at ChiaTai TianQing Pharmaceutical Group Pei Cai (2010-13), graduated as PhD, currently pharmacist-in-charge at Hunan Provincial Maternal and Child Health Care Hospital Yu Zhao (2010-16), graduated as PhD, currently associate director of Pharmacodia (Beijing) Co. Ltd. W.-S. Fang Curriculum Vitae

Guoning Zhang (2011-15), graduated as PhD, currently research associate at Chinese Academy of Medical Sciences Shuang Yang (2011-15), master student JIngxian Zhang (2012-16), graduated as MSc Deyang Sun (2013-16), graduated as PhD, currently research associate at National Institutes of Food and Drug Control Dahui Zhang (2013-16), graduated as MSc, currently marketing staff at Zhendong Pharmaceuticals Company Jiancui (2014-17), graduated as MSc, currently PhD student at University of Kentucky, USA Shuo Li (2016-present), PhD student Hao Ma (2019-present), PhD student

Undergraduates: 12 students Lei Wang (2001), Jilin University Wenzhao Wang (2004), University Xinyuan Zhang (2006), China Pharmaceutical University Yansheng Yu (2006), Yantai University Peng Wang (2007), China Agricultural University Bing Sun (2008), Xiamen University Yuntao Ma (2009), Huazhong University of Science and Technology Lijing Zhang (2011), China Pharmaceutical University Ansong Niu (2013), Beijing University of Chinese Medicine Yuqing Jia (2015), Zhengzhou University Shuo Li (2016), University Rui Li (2017), China Pharmaceutical University

Research Associates & Visiting Scientists: 8 research associates, 2 visiting scientists and 1 postdoc Dr. Ying Zhao (2005-11), PhD (Chinese Academy of Sciences), working as research associate Dr. Ruth Matesanz (2012), PhD (Consejo Superior de Investigaciones Científicas, Spain), working as visiting scientist Dr. Jun Zhao (2010-11), PhD (Zhengjiang University), working as visiting scientist Dr. Shao-Rong Wang (2011-16), PhD (Chinese Academy of Medical Sciences), working as research associate and then promoted to research associate professor Dr. Yanmei Cui (2010-14), PhD (Beijing Normal University), working as research associate Dr. Wen-Qiang Jia (2014-16), PhD (Chinese Academy of Sciences), working as research associate Dr. Xiaoying Zhang (2016-17), PhD (Capital Normal University), working as research associate Dr. Mingyan Yang (2016-18), PhD (China Agricultural University), working as research associate W.-S. Fang Curriculum Vitae

Dr. Yue Zhou (2018-present), PhD (Beijing University of Technology), working as research associate Dr. Tian-en Wang (2018-present), PhD (Chinese Academy of Medical Sciences), working as research associate Dr. Kuldeep Singh (2019-present), PhD (Maharishi Markandeshwar University, India), working as postdoctoral fellow

Courses Taught All courses taught in IMM/CAMS are opened to MS & PhD students enrolled in Chinese Academy of Medical Sciences & Peking Union Medical College 1. Structure Modification of Natural Products 2. Chemistry of Natural Products 3. Spectral Analysis